SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on upcoming Phase 3 NSCLC trial milestones and anticipation of a BLA submission for its prostate cancer therapy, aglatimagene besadenovec. The community is actively discussing recent leadership additions, including a new Chief Commercial Officer, while speculating on the potential for strategic partnerships or future acquisition as the company transitions toward commercial readiness.

United Microelectronics Corp. is engaged in the semiconductor foundry company which provides IC fabrication services, focusing on logic and various technologies to serve all major sectors of the electronics industry. It offers complementary metal-oxide semiconductor logic wafers, mixed signal wafers, radio frequency complementary metal-oxide semiconductor wafers, embedded memory products, high voltage integrated circuits, and complementary metal-oxide semiconductor image sensors. The company was founded on May 22, 1980 and is headquartered in Hsinchu, Taiwan.

United Micro Electronics - ADR

United Microelectronics Corporation

United Microelectronics Corporation is gaining significant traction as investors pivot toward its specialized manufacturing capabilities and structural partnerships, particularly its 12nm FinFET collaboration with Intel. The community is actively discussing UMCs evolution from a mature node player into a critical AI infrastructure partner, with many long-term holders highlighting its fortress balance sheet and potential as an indispensable foundry alternative in the current semiconductor landscape.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to heightened speculation surrounding institutional positioning and potential buyout rumors, as traders monitor the company's progress in clinical trials and the commercial rollout of Casgevy. The community remains divided between long-term investors focused on the disruptive potential of gene editing and those frustrated by extended periods of price stagnation and management's capital-raising activities.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending as investors show renewed confidence in its long-term DeFi dominance, fueled by the launch of its native savings application and proactive expansion into non-EVM networks. The community remains focused on the protocol's institutional utility, consistent token buyback program, and its comparative valuation against rivals.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is generating significant investor buzz following a string of Medicare coverage approvals and a deepening commercial partnership with Tempus AI, which utilizes Personalis's NeXT Personal platform for its MRD testing. The community is actively discussing the company's long-term potential as a critical player in personalized cancer vaccines and oncological infrastructure, with many focusing on the transition from clinical volume growth to meaningful revenue realization as these coverage wins convert to commercial adoption.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as investors react to a positive quarterly earnings report that showed significant revenue growth and a shift to profitability, sparking optimism about the company's long-term fintech scale. Community discussion is focused on the potential for a short squeeze given the stock's high short interest, alongside ongoing anticipation for a court ruling that could serve as a major catalyst for the share price.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining is trending as investors weigh the stock's role as a major gold and copper player amidst heightened geopolitical tension and supply chain instability in the Middle East. The community is actively discussing Barrick's robust free cash flow and share buyback potential, while monitoring how conflict-driven energy costs and the upcoming North American IPO could impact long-term valuation.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as market participants weigh strong AI-driven growth metrics against regulatory scrutiny surrounding its autonomous vehicle operations and broader volatility in Chinese equities. Community discourse remains divided between long-term investors tracking chip and robotaxi catalysts and those wary of the stock's recent sensitivity to macroeconomic headwinds and geopolitical tensions.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is seeing heightened investor attention as market participants analyze upcoming first-quarter earnings and sector-wide stress test results while navigating broader macroeconomic volatility. Community sentiment remains active as traders debate whether the financial sector's current resilience signals a sustainable recovery or if broader economic risks warrant a more cautious, risk-managed approach.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying as investors pivot to the company's emerging solid-state transformer technology, which targets power management infrastructure for AI data centers. The stock is seeing significant attention from the community as analysts raise price targets and traders navigate heavy short interest, fueling volatility and strong upward momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...

FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

– APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment – – Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“MADRS”) score compared to baseline at 12 months after two 16 mg […]
The post FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress appeared first on Financial News Media.

Cybin (NASDAQ:HELP) Shares Up 2.7%  - Should You Buy?

Cybin (NASDAQ:HELP) Shares Up 2.7% - Should You Buy...

FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

Equity

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages

Shares of Cybin Inc. (NASDAQ:HELP - Get Free Report) have been assigned an average recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Five analysts...

Cybin (NASDAQ:HELP) Now Covered by TD Cowen

TD Cowen assumed coverage on shares of Cybin in a research report on Monday. They set a "buy" rating and a $8.00 price objective on the stock...

Cybin (NASDAQ:HELP)  Shares Down 2.1%   - Time to Sell?

Cybin (NASDAQ:HELP) Trading Down 2.1% - Here's What Happened...

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...

HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside

Jefferies highlighted the Phase 3 Approach trial for depression drug HLP003 as the next key catalyst for the stock.

Dow Futures Hold Ground After 800-Point Selloff As Oil Surge Hits Wall Street: Why MRVL, USO, COST, HELP Are Trending After-Hours

U.S. crude surged above $80 per barrel after a reported Iranian missile strike on an oil tanker.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

HELPHelus Pharma Inc.

Fundamentals

Latest HELP News